Abstract
Background: Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) differ based on academic affiliation and case volume. The primary objective examined the impact of treatment facility type, and volume on time to treatment (TTT). Secondary objectives evaluated these same facility characteristics on overall survival (OS), receipt of chemotherapy, allogeneic hematopoietic stem cell transplant (HSCT) and/or palliative care.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
